Hippo Signaling Pathway

The Hippo signaling pathway is an evolutionarily conserved serine/threonine kinase cascade that governs organ size, contact inhibition of cell proliferation, mechanotransduction of extracellular matrix stiffness, stem-cell self-renewal, and tissue regeneration across metazoans. First discovered in Drosophila melanogaster genetic mosaic screens between 1995 and 2005—where loss-of-function mutations in warts (wts), salvador (sav), hippo (hpo), or mob as tumor suppressor (mats) caused dramatic tissue overgrowth and folding resembling a hippopotamus hide—the pathway converges on two paralogous transcriptional coactivators: YAP (Yes-Associated Protein, encoded by YAP1) and TAZ (Transcriptional Coactivator with PDZ-Binding Motif, encoded by WWTR1), homologs of Drosophila Yorkie (Yki).

Unlike classical morphogen pathways (Wnt, Notch, Sonic hedgehog) that respond to a single dedicated ligand–receptor pair, the Hippo pathway integrates a broad array of architectural and biophysical cues—including high cell density, apical–basal tight junction and adherens junction integrity, actin cytoskeletal tension, integrin focal-adhesion stiffness, and G-protein-coupled receptor (GPCR) signaling. When the core MST1/2–LATS1/2 kinase cascade is ON (at high cell density or on soft extracellular matrices), phosphorylated YAP and TAZ are sequestered in the cytoplasm and degraded; when the Hippo kinase cascade is OFF (at low cell density, during wound repair, or on stiff fibrotic/tumor matrices), unphosphorylated YAP and TAZ enter the nucleus and bind TEAD1–4 transcription factors to drive cell proliferation and survival.

1. Redundant Entry Kinases: MST1/2 (STK4/STK3) and MAP4Ks

At the apex of the core cassette, the Ste20-like kinases MST1 (STK4) and MST2 (STK3) form heterotetramers with the WW-domain scaffold SAV1 (Salvador homolog 1) via C-terminal coiled-coil SARAH (Sav/Rassf/Hpo) domains. Acting in parallel with MST1/2 are seven MAP4K family kinases (MAP4K1/2/3/5 and MAP4K4/6/7), explaining why complete genetic ablation of LATS1 and LATS2 is required to fully abolish HxRxxS phosphorylation of YAP1 (at Ser61, Ser109, Ser127, Ser164, and Ser397) and TAZ (at Ser66, Ser89, Ser117, and Ser311).

2. Structural Basis of the YAP/TAZ–TEAD Interface and Palmitoylation Pocket

Neither YAP nor TAZ possesses an intrinsic DNA-binding domain. Inside the nucleus, their N-terminal TEAD-binding domain (TBD) wraps around the globular C-terminal YAP-binding domain of TEAD1, TEAD2, TEAD3, or TEAD4 across three interfaces (where interface 3, containing an α-helix and Ω-loop on YAP/TAZ, provides the bulk of the binding free energy). Notably, all four human TEAD proteins contain a deep central hydrophobic pocket that undergoes autopalmitoylation at a conserved cysteine residue—a druggable structural pocket now targeted by clinical allosteric TEAD inhibitors in oncology.

Pioneering biophysical studies by Stefano Piccolo and colleagues (2011) revealed that YAP and TAZ serve as the primary intracellular mechanotransducers that translate the physical stiffness (Young's elastic modulus E) of the extracellular matrix and cellular spreading area into transcriptional cell-fate decisions:

In addition to LATS1/2 inhibition by F-actin stress fibers (which sequester the LATS-activator Angiomotin [AMOT] and the small GTPase Rap2), atomic-force microscopy studies show that actomyosin stress fibers connected to the nuclear lamina via the LINC complex (Nesprin-1/2 and SUN1/2) mechanically flatten the cell nucleus on stiff substrates. This mechanical tension stretches nuclear pore complexes, reducing the mechanical resistance of the FG-nucleoporin permeability barrier to accelerate the importin-mediated nuclear import of YAP.

1. Reversible Hepatomegaly and Regenerative Medicine

In transgenic mice engineered by Duojia Pan and Fernando Camargo, doxycycline-inducible liver-specific overexpression of phosphorylation-resistant YAP^S127A (or conditional double knockout of Mst1/Mst2 or Nf2) causes the adult mouse liver to expand rapidly to 400–500% of its normal organ weight within weeks; remarkably, turning off the YAP transgene triggers rapid hepatocyte apoptosis that shrinks the liver back to its precise normal size. In normally quiescent adult organs such as the mammalian heart, LATS1/2 activity keeps cardiomyocyte YAP sequestered in the cytoplasm after birth; experimentally expressing active YAP5SA or deleting SAV1 in adult mouse cardiomyocytes re-awakens embryonic cardiomyocyte proliferation and regenerates the myocardium after myocardial infarction.

2. Tumor Suppressor Inactivation (NF2, LATS1/2, BAP1) and Oncogenic Gene Fusions

While somatic point mutations in YAP1 or WWTR1 themselves are rare, the Hippo pathway is one of the most frequently dysregulated signaling networks across human solid tumors:

• Neurofibromatosis Type 2 (NF2 / Merlin): Germline and somatic loss-of-function mutations in NF2 (chromosome 22q12.2, encoding the FERM-domain cortical scaffold Merlin that recruits LATS1/2 to the plasma membrane) unleash nuclear YAP/TAZ to drive bilateral vestibular schwannomas (acoustic neuromas), meningiomas, ependymomas, and ~40–50% of malignant pleural mesotheliomas (which also harbor frequent inactivating mutations in LATS2 and BAP1).
• Uveal Melanoma (GNAQ / GNA11): Over 85–90% of ocular uveal melanomas are driven by constitutively active Gα_q or Gα₁₁ point mutations (Gln209Leu or Arg183Cys), which activate Trio–RhoA/Rac1 to drive F-actin polymerization and nuclear YAP translocation independently of canonical LATS1/2 inhibition.
• Pathognomonic Oncogenic WWTR1 (TAZ) and YAP1 Gene Fusions:
  • Epithelioid Hemangioendothelioma (EHE): Over 90% of this malignant vascular sarcoma are defined by a pathognomonic t(1;3)(p36;q25) chromosomal translocation generating a WWTR1–CAMTA1 fusion protein (or, in ~10%, a YAP1–TFE3 fusion) that retains the N-terminal TEAD-binding domain of TAZ fused to the C-terminal transcriptional activation and nuclear localization domains of CAMTA1, rendering the chimeric protein fully immune to LATS1/2 cytoplasmic sequestration.
  • Supratentorial Ependymoma: A recurrent subset of pediatric supratentorial ependymomas is driven by YAP1–MAMLD1 gene fusions.
• Clinical TEAD Inhibitors (e.g., VT3989, IAG933, IK-930): Small molecules that covalently or non-covalently occupy the central palmitate-binding pocket of TEAD1–4 disrupt the YAP/TAZ–TEAD complex and have demonstrated clinical responses in NF2-mutant malignant mesothelioma and WWTR1–CAMTA1 epithelioid hemangioendothelioma.

• Wu, S., Huang, J., Dong, J., & Pan, D. (2003). hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell, 114(4), 445–456. Google Scholar
• Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., ... & Piccolo, S. (2011). Role of YAP/TAZ in mechanotransduction. Nature, 474(7350), 179–183. Google Scholar
• Yu, F. X., Zhao, B., & Guan, K. L. (2015). Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell, 163(4), 811–828. Google Scholar
• Moya, I. M., & Halder, G. (2019). Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine. Nature Reviews Molecular Cell Biology, 20(4), 211–226. Google Scholar